MeSH tree: D23.050.301
No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating them with chemotherapy or radiation—which have undesirable side effects—what if we could train our ...
Dec 10, 2025
0
25
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is ...
Dec 10, 2025
0
22
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
9
Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers around 2–3%, and median ...
Nov 25, 2025
0
191
HLA compatibility is considered the key criterion for selecting donors for allo-HSCT. DKMS study data presented at the DGHO Annual Meeting 2025 in Cologne indicate the biological age of donors has a greater influence on transplant ...
Nov 19, 2025
0
16
In a surprising discovery, a "sticky molecule" that occurs naturally in our blood vessels could be both a culprit behind blood clots and organ failure during COVID and long COVID and the key to new treatments to counter COVID-related ...
Nov 17, 2025
0
19
In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and aggressors, shaping how the disease progresses.
Nov 5, 2025
0
16
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, ...
Oct 22, 2025
0
15
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.
Oct 22, 2025
0
44
An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, that could be a new treatment for a group of lung cancer patients who have few options today.
Oct 17, 2025
0
31
